One approach to gene therapy for AIDS is to block the replication of human immunodeficiency virus type 1 (HIV-1) by inhibiting the tat gene, whose product activates the expression of all HIV-1 genes. To accomplish this, we constructed an antitat gene expressing an RNA with dual (polymeric TAR and antisense-tat) function in an attempt to both sequester Tat protein and block its translation from mRNA. A minigene consisting of the antitat gene driven by the HIV-1 long terminal repeat was inserted into a double-copy retrovirus vector, such that antitat expression would be upregulated only in HIV-1-infected cells. After transduction of a T-lymphocytic cell line (Molt-3) the antitat gene inhibited HIV-1 replication. This inhibition was inversely correlated with the virus infectious dose. Virus replication was also inhibited for 5 months in two different T-cell lines after they had been infected at a high multiplicity of infection, suggesting that the antitat gene may be effective over long periods. Importantly, antitat blocked the replication and the cytopathic effect of HIV-1 in human peripheral blood mononuclear cells and led to as much as 4,000-fold inhibition of the replication of an HIV-1 field isolate as well as HIV-1 prototypes maintained in culture. These results suggest that antitat gene therapy has potential use for blocking HIV-1 replication in infected individuals.
One therapeutic strategy for human immunodeficiency virus type 1 (HIV-1)-infected individuals is to reconstitute the immune system autologously with cells which are rendered nonpermissive for HIV-1 replication. Gene therapy could provide one approach to this goal by stably transducing target cells of HIV-1 infection with a vector expressing an inhibitory gene that is able to block HIV-1 replication. To be effective, such an inhibitory gene should be integrated for long-term effects and express the inhibitory product in all HIV-1-infected cells. Key factors for the success of this strategy include approaches which prevent the formation of escape mutants or viral resistance, a major problem in current HIV-1 treatments. For example, escape mutants should be less likely to occur if the inhibitory molecule could confer multiple constraints on HIV-1 in such a way that escape from therapy would require multiple simultaneous mutations. In addition, the expression of the inhibitory gene should be regulated, like all cellular genes, to avoid potential problems caused by constitutive long-term expression; after integration, the protective gene should not significantly alter cell viability or function.
The tat gene product of HIV-1 is a key target for gene therapy not only because it is an early transactivator of the expression of all HIV-1 genes (1, 10, 33) but also because it may play an important role in the pathogenesis of AIDS and associated malignancies as both an extracellular protein and an activator of cellular gene expression (4, (12) (13) (14) (15) . Another reason to choose tat as a target for HIV-1 gene therapy is because portions of the primary and secondary sequences of the Tat activation response element (TAR) must be maintained for correct function. Thus, there are further constraints on tat in terms of its own primary, secondary, and tertiary structures to ensure the correct tat-TAR binding necessary for HIV-1 replication. This suggests that mutational escape from a therapy which sequesters tat through delivery of TAR decoys requires simultaneous tat and TAR mutations in such a way as to not only preserve the interaction of these two molecules but also maintain the ability to activate HIV-1 replication.
We have previously shown that cotransfection of two tatinhibitory genes, polymeric TAR and antisense-tat (AS-TAT), has additive effects in blocking HIV-1 gene expression (9) . To further develop this strategy for HIV-1 gene therapy, a new inhibitory gene was constructed to express a unique, dualfunction inhibitory RNA molecule. This RNA interferes with Tat by inhibiting the translation of the tat mRNA (by an antisense mechanism) and by blocking the function of Tat which has escaped from the antisense protection (by polymeric TAR, which sequesters the Tat protein). We report here that in the presence of autoregulation (activation of the transcription of the tat-inhibitory gene by the Tat protein from HIV-1), which does not allow overexpression of the inhibitory RNA, this dual-function inhibitory RNA successfully inhibits virus replication in both immortalized T cells and primary peripheral blood-derived human T lymphocytes.
MATERIALS AND METHODS
Molecular cloning. The anti-tat gene (Fig. 1A) was constructed by ligation of the HIV-1 long terminal repeat (LTR)-25TAR (21) and the AS-TAT II gene (designated as AS-TAT) described previously (9): pLTR25TAR was digested with BamHI, blunt ended, and ligated with the blunt-ended AS-TAT DNA fragment (PstI). The orientation of the AS-TAT DNA fragment was determined by restriction enzyme digestions. The LTR-25TAR-AS-TAT cassette was then placed into the 3Ј LTR of a double-copy retrovirus vector (G3) (Genetic Therapy, Inc., Gaithersburg, Md.) in both orientations by blunt-end ligation. G3 is derived from the G1 retrovirus vector (24) by insertion of a multiple-cloning site into the U3 region of the 3Ј LTR as described by Hantzopoulos et al. (17) . The structure of the retrovirus vectors containing the antitat gene (Fig. 1B) was confirmed by restriction enzyme analysis.
Transient gene transfer of inhibitory plasmids. To demonstrate inhibition of Tat transactivation, COS cells were transfected with different plasmids by liposome-mediated gene transfer with Lipofectin (Boehringer Mannheim Biochemicals, Indianapolis, Ind.) as specified by the manufacturer. LTR-CAT plasmid (2 g) was used as a reporter of HIV-1 gene expression, and LTR-TAT plasmid (0.7 g) was used as the transactivator (20) . Samples (1 g) of the different inhibitory or control plasmids were also cotransfected into these cells. Chloramphenicol acetyltransferase (CAT) activity was determined as described previously (28) .
Production of amphotropic retrovirus vectors. To avoid deletions or rearrangements during packaging, plasmids containing the antitat retrovirus vector (Fig. 1B) were linearized (with NdeI) to permit integration outside of the retrovirus vector cassette. Linearized plasmids were then transfected into the PA317 amphotropic packaging cell line (26) and selected with G418 (500 g/ml, active drug). Resistant colonies were pooled, and supernatants were collected for gene transfer experiments. The intactness of the inhibitory gene in the retrovirus vectors was verified by Southern blot experiments.
Gene transfer and HIV-1 infection of immortalized T cells. Molt-3 cells, cultured in RPMI medium supplemented with 15% fetal calf serum, were transduced with medium from vector-producing cells, and G418 (1 mg/ml, active drug)-resistant cell populations were selected without single-cell cloning. These populations were challenged with HIV-1 HTLV-IIIB (multiplicity of infection [MOI] , 0.01 to 1). Supernatants were collected twice a week, and cells were split into portions containing 0.5 ϫ 10 6 cells per ml. Virus replication was monitored by p24 antigen capture assay (Coulter, Hialeah, Fla.), and the number of viable cells was determined as described by Pauwels et al. (30) .
Gene transfer and infection of primary lymphocytes. Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood of normal donors by Ficoll-Hypaque density gradient centrifugation, activated with phytohemagglutinin (Difco, Detroit, Mich.), and cultured in RPMI medium supplemented with 15% fetal calf serum and 100 U of interleukin-2 (Boehringer Mannheim Biochemicals) per ml. After 2 days, aliquots of PBMCs (10 6 cells per ml) were transduced repeatedly with medium from vector-producing cells and selected with G418 (250 or 500 g/ml, active drug) for 10 days. Following recovery (2 days), cells were infected with HIV-1. Supernatants were collected twice a week, and cells were split into portions containing 10 6 cells per ml. HIV-1 replication was monitored by p24 antigen capture assay (Coulter), and viable-cell numbers were assessed as described by Pauwels et al. (30) .
Determination of the T-cell phenotype by flow-cytometric analysis. To quantitate the depletion of CD4 ϩ T cells after HIV-1 infection, PBMCs were washed and treated with fluorochrome-labeled monoclonal antibodies directed against CD4 and CD8 antigens (Becton Dickinson, San Jose, Calif.) at 2 g/ml. The cells were washed again, fixed with 2% paraformaldehyde, and analyzed in a flow cytometer (Becton Dickinson).
PCR analysis. To verify the enrichment through G418 selection of transduced PBMCs, genomic DNA was isolated from the transduced cells before and after G418 selection. PCR standards were prepared by mixing (0 to 30%) genomic DNA isolated from the G1 vector producer (PA317) cell line which contains one copy of the neomycin phosphotransferase gene per cell with genomic DNA isolated from the PA317 cell line. Standard PCRs were carried out in PerkinElmer Cetus equipment with primers complementary to the neo gene (5ЈGGTG GAGAGGCTATTCGGCTATGA and 5ЈATCCTGATCGACAAGACCGGC TTC).
RESULTS

Mode of action of the antitat gene.
A heterologous minigene containing a modified HIV-1 LTR (20) followed by 25 repeats of the TAR sequence contiguous with an AS-TAT molecule was constructed (9) (Fig. 1A) . The expression of this construct, designated antitat, is dependent on Tat activation since it is driven by the HIV-1 LTR (1, 20, 33) . Thus, the antitat gene should be expressed only in cells containing the Tat protein.
The mode of action is illustrated in Fig. 2A . Tat produced by the provirus or taken up by the cell from the extracellular fluid (13, 15) activates transcription of both viral and antitat RNA. antitat RNA, on the other hand, decreases the amount of Tat protein, resulting in less proviral activation and also downregulation of the antitat gene. This activation and inhibition leads to an equilibrium between Tat and antitat; consequently, neither Tat nor antitat can be overexpressed (autocrine regulation).
antitat uses two different mechanisms to inhibit Tat function: the polymeric TAR RNA can bind and sequester the Tat protein in the nucleus (21) , and the AS-TAT RNA can inhibit the translation of the tat mRNA in the cytoplasm (9) . We have previously shown that polymeric TAR can almost completely block Tat-induced activation of HIV-1 gene expression (21) . Therefore, we used suboptimal conditions (no molar excess of Figure 2B shows that LTR-25TAR inhibits 81% of Tat transactivation, AS-TAT inhibits 23%, and the dual-function antitat gene (lane 4) inhibits 94%. A similar result (90% inhibition) was obtained by cotransfection of the LTR-25TAR plasmid with the AS-TAT plasmid (lane 7), indicating that the combination of two tat-inhibitory genes has an additive effect in blocking HIV-1 gene expression (9) . Our experiments further demonstrate that the activity of the anti-tat gene depends on both inhibitory mechanisms, i.e., the polymeric TAR and the AS-TAT RNA components. Short-term inhibition of HIV-1 replication. Replicationdefective retrovirus vectors have already been used in experimental clinical trials to deliver and stably integrate a foreign gene into human cells (reviewed in reference 27). Therefore, the antitat gene was inserted into a Moloney murine leukemia virus-based vector, G3 (17, 24) , with the insert in both forward and reverse orientations. These constructs (Fig. 1B) were stably transfected into the amphotropic packaging line, PA317. Southern blot analysis of transfected-cell DNA demonstrated the preservation of the structure of the introduced plasmids. Medium from vector-producing cells was collected to assess the efficacy of the antitat gene in both immortalized and primary lymphocytes.
The anti-HIV-1 activity of the antitat gene was initially evaluated by transduction of a CD4 ϩ T-cell line, Molt-3. G418-resistant cell populations were obtained without singlecell cloning and challenged with HIV-1 HTLV-IIIB at various MOIs. At a very high MOI of 1, HIV-1 replication was blocked for up to 7 days (Fig. 3A) . At this MOI, no differences were seen in the forward-and reverse-oriented anti-tat gene vectors. In contrast, the G1 vector (not containing the antitat gene) used as a control did not show any antiviral activity. In parallel experiments, as the MOI was decreased 10-and 100-fold ( Fig.  3B and C) , the time frame of complete inhibition of viral spread increased up to 40 days for the forward vector (DCantitat/30) and 14 days for the reverse orientation vector (DC-antitat/23).
Long-term inhibition of HIV-1 replication. One advantage of this gene therapy strategy is that the inhibitory gene is integrated and can potentially prevent virus replication permanently. The long-term antiviral effect of the antitat gene in transduced Molt-3 cells infected with HIV-1 HTLV-IIIB at a high MOI of 1 was evaluated. Importantly, antiviral activity persisted for 5 months (Fig. 4A ). Although cells transduced by both antitat and the control vectors showed p24 antigen production shortly after HIV-1 infection because of the higher MOI, the levels were 20-to 30-fold lower in antitat-transduced cells than in cells transduced with the control vector. The viability of the protected cells was comparable to that of the uninfected ones, in contrast to the massive syncytium formation and death of the HIV-1-infected control cells. For example, 5 months after HIV-1 infection, antitat-transduced cells were alive and maintained a normal histologic appearance. At this time, very low but detectable levels of p24 antigen were measured, which is consistent with the expected autocrine control of antitat gene expression. This indicates that the regulatory interactions between Tat and antitat are sufficient to control virus replication for several months in Molt-3 cells even after a high challenge dose of virus.
Comparable results were obtained with another CD4 ϩ Tcell line, CEM-SS (Fig. 4B) ; however, in this case, cells transduced with the control vector were not killed after a high-MOI challenge. In the initial phase of the infection there was only about 70% inhibition of HIV-1 replication; however, after 200 days the inhibition exceeded 3,000-fold (p24 production by G1 vector-transduced cells was 419 ng/10 6 cells versus 0.13 ng/10 6 cells with the DC-antitat/30). These results again suggest that the antitat gene can be effective for long-term inhibition of HIV-1.
Retrovirus vector-mediated gene transfer into PBMCs. Retrovirus vector-mediated gene delivery is characterized by lowefficiency gene transfer into activated PBMCs. Therefore, to demonstrate the antiviral efficacy of the antitat genes in these cells, augmentation of the relative amount of transduced cells is required. However, the presence of the neomycin phospho- transferase gene in the retrovirus vectors permits cells to grow in medium supplemented with G418. Selection of primary lymphocytes is extremely difficult, because cells isolated from different donors have different sensitivities to G418 and because primary PBMCs can be grown with great difficulty with interleukin-2 for periods greater than a few months. PBMCs isolated from normal donors were transduced either with the antitat or with the control retrovirus-vector supernatants. The percentage of transduced PBMCs was estimated before and after selection by semiquantitative PCR with primers targeting the neomycin phosphotransferase gene. Figure 5 shows that under our experimental conditions, the efficiency of transduction of activated PBMCs by amphotropic retrovirus vectors was between 0.3 and 5% before selection, whereas G418 selection led to a significant increase (30%) of the transduced cell population.
Inhibition of HIV-1 replication in primary lymphocytes. Primary PBMCs are among the target cells of HIV-1 infection. To demonstrate the antiviral activity of antitat gene therapy, retrovirus vector-transduced and G418-selected PBMCs were challenged with HIV-1 HTLV-IIIB . antitat inhibited HIV-1 HTLV-IIIB replication in primary cells (Fig. 6A ) in a manner similar to the inhibition obtained with immortalized T-cell lines (Fig. 3C) . The antitat gene oriented in the forward direction with respect to the vector backbone (DC-antitat/30) was a more effective inhibitor of HIV-1 replication in PBMCs than was the gene in the reverse orientation (DC-antitat/23). One possible reason for this difference is that DC-antitat/30 expression is not strictly dependent on Tat expression, because the full-length vector RNA transcribed from the 5Ј Moloney murine leukemia virus LTR also contains antitat sequences which should have antiviral activity. Presumably, the activity of DC-antitat/23 is dependent only on Tat expression. At lower HIV-1 challenge doses (MOI, 0.001), the antiviral activities of the two antitat vectors were the same, and both completely inhibited HIV-1 replication (p24 was not detectable 25 days after infection), in contrast to the control vector (281 pg of p24/10 6 cells). The antitat gene not only blocked HIV-1 replication but also protected CD4 ϩ lymphocytes from the cytopathic effect of the virus. antitat and control vector-transduced primary lymphocytes were selected and infected with HIV-1 HTLV-IIIB . At 3 weeks after challenge, CD4 and CD8 subsets were analyzed by flow cytometry. We found (Fig. 6B ) that the antitat gene protected CD4 ϩ cells, in contrast to the results with the control vector, when the majority of CD4 ϩ cells were killed. These results demonstrate that antitat gene therapy not only inhibits HIV-1 replication and hinders virus spread but also prevents the killing of CD4 ϩ lymphocytes. Inhibition of the replication of a field isolate of HIV-1. One objection to the use of laboratory strains of HIV-1 for in vitro evaluation of antiviral agents is that passage through immortalized cell lines introduces the theoretical possibility of attenuation of the virulence of the HIV-1 isolate. Consequently, in addition to the above studies involving a common laboratory strain (HIV-1 HTLV-IIIB ), the antiviral activities of antitat vectors were evaluated by challenging the transduced cells with a primary clinical HIV-1 isolate (strain 3935; a gift from R. Redfield, Walter Reed Army Institute of Research, Rockville, Md., and P. Markham, Advanced BioSciences, Kensington, Md.). This HIV-1 isolate was never grown in immortalized cell lines but was passaged only in primary PBMCs. Normal PBMCs were transduced with antitat or control vectors, selected in G418 as above, and infected with HIV-1 3935. Both antitat vectors (forward and reverse orientations) inhibited HIV-1 3935 replication by more than 2,000-fold (Fig. 6C ). These observations indicate that the antitat gene therapy is not limited to its effectiveness against a particular laboratory HIV-1 strain but that antitat is able to block replication of field isolates of HIV-1 obtained from infected individuals.
DISCUSSION
The antitat inhibitory gene has several important features relevant to its therapeutic potential. First, its expression is dependent on activation by Tat, and therefore the antitat gene should be expressed only in cells in which the Tat protein is present. We have previously demonstrated that polymeric TAR transcription from the HIV-1 LTR is very low in the absence of Tat and is highly activated if Tat is present (22) . However, antitat not only is regulated by Tat but also inhibits Tat. This autocrine regulation provides a mechanism for amplifying and/or prolonging the response to Tat and does not permit overproduction of the inhibitory RNA when it is unnecessary, i.e., in uninfected cells. Since TAR can also bind cellular factors (16, 23, 31, 32, 36) , the possibility that longterm, constitutive overexpression of TAR RNA will sequester some essential proteins could be a matter of concern. If these specific cellular factors play an important role in cellular regulation, the autocrine regulation of the antitat gene may be important in avoiding overexpression and the theoretical possibility of toxicity. Second, anti-tat is a dual-function gene, inhibiting HIV-1 Tat function through two different mechanisms, and the polymeric TAR and the AS-TAT on the same transcript have an additive inhibitory effect. Since Tat activates HIV-1 gene expression and the production of inflammatory cytokines (7, 8) , reduction of Tat production results not only in inhibition of HIV-1 replication but also in inhibition of cytokine activation. Third, the low likelihood of simultaneous mutations of Tat and TAR during virus replication and the conserved structural requirements for their interaction should make viral escape less likely than with some other approaches to therapy. In support of this hypothesis, we have demonstrated that polymeric TAR is a general inhibitor of primate lentiretroviruses, inhibiting not only HIV-1 but also the simian immunodeficiency virus SIV Mac251 (21) , and in the present work we have extended this result by showing inhibition of a field isolate of HIV-1. Fourth, polymeric-TAR binding to Tat in HIV-1-infected cells prevents its extracellular release and inhibits the activities of extracellular Tat taken up by cells (4, 12, 13) . In this respect, we have previously demonstrated that polymeric TAR inhibits the activation of Tat-defective proviruses (9) and associated cellular alterations, both of which are induced by exogenous Tat (4, 12) . Fifth, inhibition of Tat results in activation of negative-strand RNA transcripts from the 3Ј HIV-1 LTR (25) . It is possible that this RNA acts as an antisense inhibitor, in addition to the AS-TAT provided in the antitat gene. A negative-strand RNA that reflects the perfect complementary sequence of any HIV-1 variants in the cell would, of course, have an advantage over the genetically engineered AS-TAT gene.
The antiviral effect of the antitat gene is not comparable to the inhibition of Tat transactivation induced by benzodiazepine compounds (Ro5-3335 and Ro24-7429) (19) . These chemicals block Tat activation of transcription from the HIV-1 LTR, leading to inhibition of virus replication. However, there is increasing evidence that it is the interaction of Ro24-7429 with cellular factors rather than with Tat which is responsible for the antiviral activity of this compound (6, 18, 35) . This may explain the toxicity of the benzodiazepine compounds and the discrepancies in results of efficacy studies.
Since the results with the Molt-3 cell line were similar to results with the primary PBMCs, the Molt-3 cells may be appropriate for initial preclinical biologic efficacy evaluations of HIV-1-inhibitory gene transfer strategies. The complete inhibition of HIV-1 replication in primary cells also confirms that the antiviral activity of the antitat gene is more efficient at lower viral challenge doses and suggests that the spread of HIV-1 might be blocked in vivo by antitat when the viral burden is low. Therefore, we propose that antitat gene therapy will be more efficient in early intervention when the viral load is smaller (2, 11, 29) .
There are different ways to use ex vivo gene therapy against HIV-1 infection. The simplest is to transduce the inhibitory gene into PBMCs or purified CD4 ϩ lymphocytes isolated from HIV-1-infected individuals and to select and reinfuse these cells into the patient (3). The therapeutic efficacy of this approach will probably be very limited, mainly because of the low percentage of transduced T cells. Another approach is to introduce the inhibitory gene into hematopoietic stem cells. If stem cells will properly mature in patients with AIDS (5), genetically engineered cells could repopulate the immune system without allowing replication of the virus. This approach is attractive because, in theory, one treatment could lead to control of HIV-1; however, the present stem cell and gene transfer technologies have not yet been adequately developed to make this treatment feasible (34) . The ultimate goal of stem cell therapy is successful repopulation with all hematopoietic cells containing the foreign gene. Since only a small fraction of these cells are permissive for HIV-1 replication, we think that it will be important to express the inhibitory gene only in cells which become infected. Regulation of the expression of the inhibitory gene may reduce potential toxicity problems, because an inactive gene should not interfere with the proper function of the cell. Therefore, we propose the autoregulated antitat gene as a candidate for anti-HIV-1 gene therapy with lymphocytes now and with stem cells in the future as the technology is further developed.
